Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apt.17943 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Glucagon-like Peptide-1 Receptor Agonist Use with Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease: A BMI-Stratified Retrospective Study.
Spine (Phila Pa 1976)
September 2025
Department of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Providence, RI.
Study Design: Retrospective Cohort.
Summary Of Background Data: Spinal fusions are common interventions for degenerative spine disease (DSD), with increasing utilization in obese and metabolic syndrome populations. Glucagon-like peptide-1 (GLP-1) receptor agonists (RA), widely adopted for diabetes and weight management, may offer systemic benefits that exert a parallel influence on surgical outcomes.
Understanding the Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Heart Failure.
Card Fail Rev
August 2025
Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia Brescia, Italy.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for glycaemic control in patients with type 2 diabetes, have demonstrated significant cardiometabolic benefits beyond glucose regulation. These agents have multiple effects, including reducing body weight, improving insulin sensitivity, anti-inflammatory properties and enhancing endothelial function. All these mechanisms are potentially beneficial in patients with heart failure (HF), specifically those with HF with preserved left ventricular ejection fraction.
View Article and Find Full Text PDFEditorial: Advances in pharmacotherapy for alcohol use disorder: from mechanisms to clinical interventions.
Front Pharmacol
August 2025
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States.
Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT.
Diabetes Ther
August 2025
Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy.
Despite advances in cardiovascular risk reduction in type 2 diabetes (T2D), a persistent gap remains compared to individuals without diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1RA) have provided consistent cardiovascular benefits. With more cardiovascular protective agents available for diabetes management, their incremental effect may be nearing a ceiling.
View Article and Find Full Text PDFThe Weight of Cardiovascular Diseases: Addressing the Global Cardiovascular Crisis Associated with Obesity.
Glob Heart
August 2025
Santa Maria University Hospital, CAML, CCUL, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
Obesity is a growing global epidemic with significant implications for cardiovascular diseases (CVD). It couples as an independent risk factor and driver for multiple pathways leading to CVDs. Here we examine obesity's impact on CVD and propose actionable strategies.
View Article and Find Full Text PDF